Alzheimer's Disease Study

Principal Investigator: William Fuller, MD

Study Coordinator: Christi Hinker, RNC

Sub-Investigators: Matthew Malone, MD; John Erpenbach, CNP; Susan Weaver, CNP; Julie Kittelsrud, CNP; Gail Fuller, RN, Christi Hinker, RNC

Study Description: Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer’s Disease as Compared with Placebo

Overview: This study is evaluating the effectiveness of an investigational medication at slowing the impact of Alzheimer’s disease on memory and daily activities when given as an intravenous (IV) infusion once every 4 weeks.

Participants can continue taking their current Alzheimer’s medications. The investigational medication, study-related evaluations, and laboratory tests will be provided to qualified participants at no cost.

Inclusion Criteria:

• Be 55 years or older, and generally healthy.

• Have mild to moderate Alzheimer’s disease.

• Have a reliable caregiver (study partner) who can assist him or her during the study.

Contact:   Christi Hinker, RNC
Phone:    (605) 322-3084
Email:      christi.hinker@avera.org

www.ExpeditionStudy.com